Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Gastroenterology. 2016 Jan 9;150(4):911–917. doi: 10.1053/j.gastro.2015.12.040

Table 3. Exploratory SubGroup Analysis of Patients with Post-ERCP Pancreatitis.

Patients with PEP % Relative Risk Reduction (Indomethacin vs. Placebo)
Indomethacin (n=16) Placebo (n=11)

Pancreatic Stent Placement – no. (%) 8 (50) 4 (36) -28%
Suspected Sphincter of Oddi Dysfunction – no. (%) 1 (6) 1 (9) +33%
History of Post-ERCP Pancreatitis 2 (13) 1 (9) -21%
Difficult Cannulation 6 (38) 5 (45) +16%
Wire Cannulation of Pancreatic Duct – no. (%) 13 (81) 7 (64) -21%
Pancreatography – no. (%) 8 (50) 8 (73) +32%
Pancreatic Acinarization – no. (%) 2 ( 13) 0 (0) NA
Therapeutic Biliary Sphincterotomy – no. (%) 7 (44) 3 (27) -39%
Therapeutic Pancreatic Sphincterotomy – no. (%) 2 (13) 3 (27) +52%
Balloon Dilation of Biliary Sphincter – no. (%) 0 (0) 1 (9) NA
Trainee Involvement in ERCP – no. (%) 12 (75) 8 (73) -3%